Document:

Exhibit 10.1

      

     

      

    VOTING AND SUPPORT AGREEMENT

     

    This VOTING AND SUPPORT AGREEMENT (this “Agreement”)
      is made and entered into as of October 16, 2020 by and among Forian Inc., a Delaware corporation (“Parent”), on the one hand, and the undersigned securityholder (a “Securityholder”) of Helix Technologies, Inc., a Delaware corporation (the “Company”), on
      the other hand.

     

    RECITALS

     

    WHEREAS, concurrently with the execution of this Agreement, the Company, Parent and DNA Merger Sub Inc., a Delaware corporation and
      wholly owned subsidiary of Parent (“Merger Sub”), are entering into an Agreement and Plan of Merger (as amended, restated, supplemented or otherwise modified from time
      to time, the “Merger Agreement”), dated as of the date hereof, pursuant to which Merger Sub will be merged with and into the Company (the “Merger”), with the Company being the surviving entity of such Merger and a wholly owned subsidiary of Parent on the terms, and subject to the conditions, set forth in the Merger Agreement;

     

    WHEREAS, as of the date hereof, the Securityholder is the beneficial owner (for purposes of this Agreement, “beneficial owner” (including “beneficially own” and other correlative terms) shall have the meaning set forth in Rule 13d-3 promulgated under the Securities Exchange Act of
      1934, as amended, and the rules and regulations promulgated thereunder (the “Exchange Act”)) of the number of shares of Company Common Stock and the number of shares of
      Company Preferred Stock (as defined in the Merger Agreement) set forth opposite the Securityholder’s name on Schedule I hereto (such shares of Company Common Stock and
      Company Preferred Stock, together with any other capital stock of the Company, the power to dispose of or the voting power over which is acquired by a Securityholder after the date of this Agreement (including, for the avoidance of doubt, any shares
      of capital stock of the Company resulting from the conversion of any other Subject Securities), collectively, the “Subject Shares”)); and

     

    WHEREAS, as a condition to and as an inducement to Parent’s and Merger Sub’s willingness to enter into the Merger Agreement, the
      Securityholders have agreed to enter into this Agreement, to vote their Subject Shares as described herein, to the treatment of the other Subject Securities as described herein.

     

    AGREEMENT

     

    NOW, THEREFORE, in consideration of the representations, warranties, covenants and agreements contained in this Agreement, and
      intending to be legally bound hereby, the parties hereto hereby agree as follows:

     

    ARTICLE 1

      DEFINITIONS

     

    Section 1.1          General.  Capitalized terms used but not defined herein shall have the respective meanings ascribed to them in the Merger Agreement.  For all purposes of and under this
          Agreement, the following terms shall have the following respective meanings:

     

    (a)          “Constructive Sale” means, with respect to any Subject Security, a short sale with respect to such Subject Securities, entering into or acquiring an offsetting
          derivative contract with respect to such Subject Securities, entering into or acquiring a future or forward contract to deliver such Subject Securities, or entering into any other hedging or other derivative transaction that has the effect of
          either directly or indirectly materially changing the economic benefits or risks of ownership of such Subject Securities.

     

    
      
        

    

    (b)          “Expiration Date” means the earliest to occur of (i) such date and time after the Effective Time at which the Securityholders’ Subject Securities shall have been
          exercised, converted or otherwise terminated or cancelled, and such Securityholder no longer has any right or claim of ownership over any Subject Security or other equity interests of the Company or the Surviving Corporation, (ii) such date and
          time as the Merger Agreement shall be properly terminated pursuant to Article VIII of the Merger Agreement, and (iii) as to the Securityholder, the mutual written agreement of Parent and such Securityholder to terminate this Agreement.

     

    (c)          “Transfer” means, with respect to any Subject Security, the direct or indirect assignment, sale, transfer, assignment, tender (into a tender offer, exchange offer or
          otherwise), pledge, hypothecation, or the grant, creation or suffrage of a Lien upon, or the gift, placement in trust, or the Constructive Sale or other disposition (including by merger or any other conversion into securities or other
          consideration) of such Subject Securities (including transfers by testamentary or intestate succession or otherwise by operation of Law) or any right, title or interest therein (including any right or power to vote to which the holder thereof may
          be entitled, whether such right or power is granted by proxy or otherwise), or any change in the record or beneficial ownership of such Subject Securities, and any agreement, arrangement or understanding, whether or not in writing, to effect any
          of the foregoing.

     

    (d)          “Voting Period” means the period commencing on the date hereof through and including the Expiration Date.

     

    ARTICLE 2

      AGREEMENT TO VOTE AND IRREVOCABLE PROXY

     

    Section 2.1          Agreement to Vote.  The Securityholder hereby unconditionally and irrevocably agrees that, during the Voting Period, at every meeting of the stockholders of the Company
          called with respect to any of the following, and at every adjournment or postponement thereof, and on every action or approval by written consent of stockholders of the Company with respect to any of the following, the Securityholder agrees that
          it shall, or shall cause the holder of record on any applicable record date to, appear at such meeting, in person or by proxy, or otherwise cause all of such Securityholder’s Subject Shares to be counted as present thereat for purposes of
          calculating a quorum and vote (or cause to be voted), in person or by proxy, such Securityholder’s Subject Shares or deliver (or cause to be delivered) a written consent in respect of such Subject Shares:

     

    (a)          in favor of (i)
          adoption of the Merger Agreement and approval of the Merger, (ii) each of the actions contemplated by the Merger Agreement in respect of which approval of the Company’s stockholders is requested, and (iii) any proposal or action in respect of
          which approval of the Company’s stockholders is requested that could reasonably be expected to facilitate the Merger and the other transactions contemplated by the Merger Agreement (including, for the avoidance of doubt, any proposal to adjourn
          or postpone such meeting of the Company’s stockholders to a later date if there are not sufficient votes for adoption of the Merger Agreement and the transactions contemplated thereby, including the Merger); and

     

    
      
        

    

    (b)          against (i) any
          action, proposal, transaction or agreement that would (A) constitute a breach in any respect of any covenant, representation or warranty or any other obligation or agreement of the Company under the Merger Agreement or of such Securityholder
          under this Agreement or (B) that reasonably would be expected to prevent, impede, frustrate, interfere with, delay, postpone or adversely affect the Merger or any of the other transactions contemplated by the Merger Agreement or the consummation
          of the Merger or such other transactions, (ii) any Alternative Proposal (as defined in the Merger Agreement) or any proposal relating to an Alternative Proposal, (iii) any stock purchase agreement or other agreement relating to a merger,
          consolidation, combination, sale, lease or transfer of a material amount of assets of the Company or any of its Subsidiaries, reorganization, recapitalization, dissolution, liquidation or winding up of or by the Company or any of its
          Subsidiaries, or any other action or transaction involving the Company (other than the Merger Agreement and the Merger), (iv) any change in the present capitalization or dividend policy of the Company or any amendment or other change to the
          governing or organizational documents of the Company or any Company Subsidiary (as defined in the Merger Agreement), (v) any proposal in opposition to approval of the Merger Agreement or in competition with or materially inconsistent with the
          Merger Agreement, or (vi) any proposal or action that would result in any of the conditions set forth in Article VII of the Merger Agreement or any obligations of the Company not being fulfilled.

     

    The Securityholder agrees not to, and shall cause its Affiliates not to, enter into any agreement, commitment or arrangement with any Person, the
      effect of which would be inconsistent with or violative of the provisions and agreements contained in this Article 2.

     

    Section 2.2          Grant of Irrevocable Proxy.  The Securityholder hereby irrevocably appoints Parent and any designee of Parent, and each of them individually, as such Securityholder’s
          proxy and attorney-in-fact, with full power of substitution and resubstitution, to vote at any annual or special meeting of stockholders at which any of the matters described in Section 2.1 is to be considered during the Voting Period, with
          respect to such Securityholder’s Subject Securities as of the applicable record date, in each case solely to the extent and in the manner specified in Section 2.1; provided, however, that such Securityholder’s grant of the proxy contemplated by
          this Section 2.2 shall be effective if, and only if, such Securityholder has not delivered to the Secretary of the Company, at least two (2) Business Days prior to the applicable meeting, a duly executed irrevocable proxy card directing that such
          Securityholder’s Subject Securities be voted in accordance with Section 2.1.  This proxy, if it becomes effective, is given to secure the performance of the duties of such Securityholder under this Agreement, and its existence will not be deemed
          to relieve such Securityholder of its obligations under this Agreement.  This proxy shall expire and be deemed revoked automatically on the Expiration Date.

     

    Section 2.3          Nature of Irrevocable Proxy.  The proxy and power of attorney granted pursuant to Section 2.2 by the Securityholder is irrevocable during the Voting Period, shall be
          deemed to be coupled with an interest sufficient in law to support an irrevocable proxy and shall revoke any and all prior proxies granted by the Securityholder with regard to such Securityholder’s Subject Securities and the Securityholder
          acknowledges that the proxy constitutes an inducement for Parent and Merger Sub to enter into the Merger Agreement. The power of attorney granted by the Securityholder is a durable power of attorney and shall survive the bankruptcy, dissolution,
          death or incapacity of such Securityholder.

     

    
      
        

    

    Section 2.4          No Obligation as Director or Officer. Nothing in this Agreement shall be construed to impose any obligation or limitation on votes or actions taken by any director,
          officer, employee, agent or other representative of any Securityholder or by any Securityholder that is a natural person, in each case, in his or her capacity as a director or officer of the Company.  The Securityholder is executing this
          Agreement solely in such capacity as a record or beneficial holder of the Subject Securities.

     

    ARTICLE 3

      NO TRANSFER OF SUBJECT SECURITIES OR VOTING RIGHTS

     

    Section 3.1          Except
          as otherwise expressly permitted by this Agreement or the Merger Agreement, the Securityholder hereby agrees that, during the Voting Period, such Securityholder shall not:

     

    (a)          cause or permit,
          or commit or agree to cause or permit, any Transfer of any of such Securityholder’s Subject Securities or take any other action that would in any way delay, restrict, limit or interfere with the performance of such Securityholder’s obligations
          hereunder or the transactions contemplated hereby or by the Merger Agreement;

     

    (b)          deposit, or
          permit the deposit of, or act in concert with any Person to deposit, any of such Securityholder’s Subject Securities in a voting trust, grant any proxy or power of attorney in respect of such Securityholder’s Subject Securities, enter into any
          voting agreement or similar arrangement, commitment or understanding with respect to such Securityholder’s Subject Securities or otherwise commit or suffer any act that could restrict or affect such Securityholder’s legal power or right to vote,
          or exercise a written consent with respect to, the Subject Securities;

     

    (c)          acquire, offer
          or propose to acquire or agree to acquire, directly or indirectly, any additional securities (or options, rights or warrants to purchase, or securities convertible into or exchangeable for, such securities) of the Company;

     

    (d)          form, join,
          encourage, influence, advise or in any way participate in any “group” (as such term is defined in Section 13(d)(3) of the Exchange Act) with any Persons with respect to any securities of the Company;

     

    (e)          act in concert
          with any person to make, or in any manner participate in, directly or indirectly, a “solicitation” of “proxies” or consents (as such terms are used in the proxy solicitation rules of the SEC) or powers of attorney or similar rights to vote, or
          seek to advise or influence any Person with respect to the voting of, any shares of Company Capital Stock in connection with any vote or other action with respect to a business combination transaction, other than to recommend that stockholders of
          the Company vote in favor of adoption of the Merger Agreement and any proposal or action in respect of which approval of the Company’s stockholders is requested that could reasonably be expected to facilitate the Merger and the other transactions
          contemplated by the Merger Agreement and otherwise as expressly provided by Section 2.1; or

     

    
      
        

    

    (f)          commit or agree
          to take any of the foregoing actions.

     

    Notwithstanding the foregoing, if a Securityholder is a natural person, such Securityholder may Transfer any such Subject Securities by will, other
      testamentary document or under the laws of intestacy upon the death of such Securityholder.

     

    Section 3.2          Any
          Transfer or other action taken or effected in violation of this Article 3 shall, to the fullest extent permitted by Law, be void ab initio and of no
          force or effect, and the Company may decline to give effect to such transfer in its books and records and those of its agents.

     

    ARTICLE 4

      NO SOLICITATION OF ALTERNATIVE PROPOSALS

     

    Section 4.1          The
          Securityholder (in such Securityholder’s capacity as such) shall, and shall cause its Affiliates, and its and their respective officers, directors, managers or employees, and shall instruct its and their respective accountants, consultants, legal
          counsel, financial advisors, agents and other representatives to: (a) immediately cease any existing solicitations, discussions or negotiations with any Persons that may be ongoing with respect to any Inquiry and (b) not, and not publicly
          announce any intention to, directly or indirectly, (i) solicit, initiate, knowingly encourage or facilitate any Inquiry (it being understood and agreed that answering unsolicited phone calls shall not be deemed to “facilitate” for purposes of, or
          otherwise constitute a violation of, this Section 4.1), (ii) furnish non-public information to any Person in connection with an Inquiry or an Alternative Proposal or (iii) enter into, continue or otherwise participate in any discussions or
          negotiations with any Person with respect to an Inquiry or an Alternative Proposal.

     

    Section 4.2          The
          Securityholder shall (a) notify Parent reasonably promptly (but in no event more than twenty-four (24) hours) following such Securityholder’s receipt of any Alternative Proposal or any Inquiry or request for non-public information relating to the
          Company or any Company Subsidiary by any Person who has made or could reasonably be expected to make any Alternative Proposal, (b) advise Parent in writing of (i) the receipt of such Alternative Proposal, Inquiry or request, (ii) the identity of
          the Person making any such Alternative Proposal, Inquiry or request, and (iii) the terms and conditions of such Alternative Proposal or potential Alternative Proposal or the nature of the information requested, (iv) as reasonably promptly as
          practicable provide to Parent: (1) a copy of such Alternative Proposal or potential Alternative Proposal, if in writing, or a written summary of the material terms of such Alternative Proposal, if oral, and (2) copies of all written requests,
          proposals, correspondence or offer, including proposed agreements received by such Securityholder or any of its Representatives; and (c) keep Parent reasonably informed on a reasonably current basis, or upon Parent’s reasonable request, (i) of
          the status and material terms of (including amendments or revisions or proposed amendments or revisions to) each such Alternative Proposal or potential Alternative Proposal, and (ii) as to the nature of any information requested of such
          Securityholder with respect thereto.

     

    
      
        

    

    ARTICLE 5

      TREATMENT OF SECURITIES; TERMINATION OF CERTAIN AGREEMENTS

     

    Section 5.1          Company Preferred Stock.  A Securityholder that is the beneficial owner of Company Preferred Stock agrees (a) other than as provided in this Section 5.1, not to convert
          or elect to convert, all or in part, any shares of Company Preferred Stock into shares of Company Common Stock; and (b) that, notwithstanding anything to the contrary in the Company’s organization documents or any Contract relating to such
          Securityholder’s shares of Company Preferred Stock to the contrary, effective as of the time that is immediately prior to the Effective Time, (i) each share of Company Preferred Stock held by such Securityholder shall automatically convert into
          1.046 shares of Company Common Stock and (ii) each such share of Company Preferred Stock shall deemed to be cancelled on the books and records of the
          Company and shall cease to be outstanding.  The Securityholder releases Parent, Merger Sub, the Company and the Surviving Corporation from any and all claims related to such Securityholder’s shares of Company Preferred Stock upon their conversion
          as set forth in this Section 5.1.

     

    Section 5.2          Company Convertible Notes.  A Securityholder that is the beneficial owner of one or more Company Convertible Notes agrees (a) other than as provided in this Section
          5.2, not to convert or elect to convert, all or in part, any amount outstanding at any time under any such Convertible Promissory Note into shares of Company Capital Stock; and (b) that, notwithstanding anything to the contrary in any such
          Company Convertible Note or any other Contract relating thereto, effective as of the time that is immediately prior to the Effective Time, (i) the then-current outstanding unpaid principal and accrued but unpaid interest under each such Company
          Convertible Note (together with any other unpaid fees due thereunder, the “Convertible Amount”), shall automatically convert into that number of shares of Company
          Common Stock as is set forth in the applicable Convertible Note Conversion Agreement contemplated by the Merger Agreement, (ii) each such Company Convertible Note shall be deemed to be paid in full and shall cease to be binding upon the Company
          and the Surviving Corporation, and none of the Company, the Surviving Corporation or any of their Affiliates shall have any further obligations with respect thereto; and (iii) each of Parent, Merger Sub, the Company and the Surviving Corporation
          are hereby authorized to file any UCC-3 financing statement terminating such Securityholder’s Liens in any assets or properties of the Company or the Surviving Corporation and authorizes each of Parent, Merger Sub, the Company and the Surviving
          Corporation, or its designees, to take any other action reasonably necessary to effect the foregoing.  The Securityholder releases Parent, Merger Sub, the Company and the Surviving Corporation from any and all claims related to such
          Securityholder’s Company Convertible Notes upon their conversion as set forth in this Section 5.2.

     

    Section 5.3          Termination of Securityholder Contracts.  A Securityholder that is party to a Securityholder Contract (as defined below) agrees that, notwithstanding anything to the
          contrary in any such Securityholder Contract, effective as of the time that is immediately prior to the Effective Time, each such Securityholder Contract shall automatically terminate as to such Securityholder and cease to be binding upon the
          Company and the Surviving Corporation as to such Securityholder, and none of Parent, the Company, the Surviving Corporation or any of their Affiliates (including MOR) shall have any further obligations as to such Securityholder with respect
          thereto.  For purposes of this Agreement, “Securityholder Contract” means, with respect to Securityholder, any Contract to which such Securityholder and the Company
          or any of its Subsidiaries is party, but it shall not include the employment agreements with Scott Ogur or Zachary Venegas or the management agreement with the Rose Capital entities (the “Excluded Contracts”), each of which will terminate
          immediately after the Effective Time provided that the terms thereof will continue to be binding to extent an obligation was triggered or incurred before termination.

     

    
      
        

    

    ARTICLE 6

      ADDITIONAL COVENANTS OF THE SECURITYHOLDERS

     

    Section 6.1          General Covenants.  No Securityholder shall: (a) enter into any Contract with any Person or take any other action that violates or conflicts with or would reasonably be
          expected to violate or conflict with, or result in or give rise to a violation of or conflict with, the representations, warranties, covenants and obligations of the Securityholders under this Agreement or that would make any representation or
          warranty of any Securityholder contained in this Agreement untrue or incorrect; or (b) take any action that would restrict, impair or otherwise affect such Securityholder’s legal power, authority and obligation to comply with and to timely
          perform such Securityholder’s covenants and obligations under this Agreement.  The Securityholder further agrees that it shall use its commercially reasonable efforts to cooperate with Parent, the Company and their respective Subsidiaries to
          effect the transactions contemplated hereby and the Merger Agreement.

     

    Section 6.2          No Appraisal or Other Claims. The Securityholder: (a) knowingly, voluntarily, intentionally, unconditionally and irrevocably waives and agrees not to exercise any right
          (including under Section 262 of the DGCL) to demand appraisal of any of the Subject Securities or right to dissent from the Merger that such Securityholder may have (collectively, “Appraisal Rights”) or to receive notice of any right to seek Appraisal Rights in connection with the Merger; (b) agrees not to commence, participate in or voluntarily aid in any way any claim or
          proceeding to seek (or file any petition related to) Appraisal Rights in connection with the Merger; and (c) agrees not to commence, participate in or voluntarily aid in any way, and will take all actions necessary to opt out of, any class in any
          class action with respect to, any claim, derivative or otherwise, against Parent, Merger Sub, the Company or any of their respective Representatives or successors relating to the negotiation, execution or delivery of this Agreement or the Merger
          Agreement or the consummation of the Merger, including any claim (x) challenging the validity of, or seeking to enjoin the operation of, any provision of this Agreement or the Merger Agreement, (y) alleging a breach of any fiduciary duty of the
          Company Board in connection with the Merger Agreement or the transactions contemplated thereby, or (z) making any claim with respect to any disclosures in any filing, statement, report or document filed with or furnished to the SEC connection
          with the Merger Agreement, the Merger or any other transaction contemplated by the Merger Agreement; provided, that the foregoing covenants shall not be deemed a consent to or waiver of any rights of the Securityholders for any breach of this
          Agreement.

     

    
      
        

    

    Section 6.3          Confidentiality.  The Securityholder agrees, and agrees to cause its Covered Persons to and to instruct and cause its and their Representatives to, keep confidential
          all nonpublic information in their possession regarding Parent, Company and their respective Subsidiaries (including MOR in the case of Parent) to the extent such nonpublic information is in their possession (the “Confidential Information”); provided, however, that such Securityholders, their Affiliates and their respective Representatives shall not be required to maintain as confidential any
          Confidential Information that (a) becomes generally available to the public other than as a result of disclosure (x) by such Person or (y) to the knowledge of such Person, in violation of an obligation or duty of confidentiality to the Company,
          or (b) such Person is required pursuant to the terms of a valid order issued, promulgated or entered by or with any Governmental Entity of competent jurisdiction or any applicable Law to disclose to such Governmental Entity (provided, that with
          respect to this clause (b), such Person shall (i) to the extent legally permissible, prior to the disclosing of any Confidential Information, provide Parent with prompt notice of such order and provide commercially reasonable assistance and
          cooperation with all efforts of Parent, Merger Sub, the Surviving Corporation or any of their respective Subsidiaries (including MOR) in obtaining a protective order or other remedy and (ii) disclose such Confidential Information only to the
          extent required, upon advice of counsel, by such order or Law and use commercially reasonable efforts to ensure that such Confidential Information is accorded confidential treatment.

     

    Section 6.4          Communications. Unless required by applicable Law, including the Exchange Act and the rules and regulations promulgated thereunder, the Securityholder shall not, and
          the Securityholder shall cause its Affiliates and its and their Representatives not to, make any press release, public announcement or other communication with respect to the business or affairs of Parent, the Company or any of their respective
          Subsidiaries (including MOR in the case of Parent), including this Agreement and the Merger Agreement and the transactions contemplated hereby and thereby, without the prior written consent of Parent.  The Securityholder hereby (a) consents to
          and authorizes the publication and disclosure by Parent, the Company and their respective Affiliates and Representatives of such Securityholder’s identity and holding of Subject Securities, and the nature of such Securityholder’s commitments,
          arrangements and understandings under this Agreement in any public disclosure document required by applicable Law in connection with the Merger or any other transactions contemplated by the Merger Agreement or any other information required to be
          disclosed by applicable Law and (b) shall as promptly as practicable notify Parent of any required corrections with respect to any information supplied by such Securityholder specifically for use in any such disclosure document.

     

    Section 6.5          Further Assurances. From time to time, at the reasonable request of Parent and without further consideration, the Securityholder shall execute and deliver such
          additional documents and take all such further action as may be reasonably necessary or desirable to comply with its obligations under this Agreement.

     

    Section 6.6          Fiduciary Duties. This Agreement is being entered into by the Securityholders solely as a record and/or beneficial owner of the Subject Shares. Nothing in this
          Agreement shall restrict or limit the ability of the Securityholders or any of their respective Affiliates who is a director, officer or employee of the Company to take any action in his or her capacity as a director, officer or employee of the
          Company, including the exercise of fiduciary duties to the Company or its shareholders.

     

    
      
        

    

    ARTICLE 7

      REPRESENTATIONS AND WARRANTIES OF THE SECURITYHOLDERS

     

    The Securityholders hereby represent and warrant to Parent as of the date of this Agreement and as of the Company Stockholder
      Meeting as follows:

     

    Section 7.1          Power; Due Authorization; Binding Agreement. Such Securityholder has the requisite power and authority to execute and deliver this Agreement, to perform its obligations
          hereunder and to consummate the transactions contemplated hereby.  The execution and delivery of this Agreement and the consummation by such Securityholder of the transactions contemplated hereby have been duly and validly authorized by all
          necessary corporate, partnership or other applicable action on the part of such Securityholder, and no other proceedings on the part of such Securityholder are necessary to authorize this Agreement or to consummate the transactions contemplated
          hereby. This Agreement has been duly and validly executed and delivered by such Securityholder and, assuming the due and valid authorization, execution and delivery hereof by the other parties hereto, constitutes a valid and binding agreement of
          such Securityholder, enforceable against such Securityholder in accordance with its terms, except that (i) such enforcement may be subject to applicable bankruptcy, insolvency, reorganization, moratorium or other similar Laws, now or hereafter in
          effect, relating to creditors’ rights generally and (ii) equitable remedies of specific performance and injunctive and other forms of equitable relief may be subject to equitable defenses and to the discretion of the court before which any
          proceeding therefor may be brought.

     

    Section 7.2          Ownership of Shares.  (i) Such Securityholder is the beneficial owner of, and has good, valid and marketable title to, the Subject Securities set forth opposite its
          name on Schedule I, (ii) such Securityholder has sole voting power, and sole power of disposition, with respect to all of its Subject Securities, (iii) such
          Securityholder’s Subject Shares, together with the capital stock of the Company underlying the Company Convertible Notes and Company Warrants set forth on Schedule I,
          are all of the shares of Company Capital Stock that are owned, either of record or beneficially, by such Securityholder and its Affiliates (other than the other Securityholders), (iv) such Securityholder’s Subject Securities are all of the equity
          interests of the Company or any of its Subsidiaries that are owned, either of record or beneficially, by such Securityholder and its Affiliates (other than the other Securityholders); (v) other than the Company Convertible Notes set forth on Schedule I, there is no other Indebtedness or other amounts outstanding on behalf of the Company or any of its Subsidiaries in favor of such Securityholder or any of
          its Affiliates; (vi) the Subject Securities owned by such Securityholder are free and clear of all Liens, other than any Liens created by this Agreement, the underlying agreements pursuant to which such s were issued or as imposed by applicable
          securities Laws and (vii) such Securityholder has not appointed or granted any proxy inconsistent with this Agreement, which appointment or grant is still effective, with respect to the Subject Securities.

     

    Section 7.3          No Conflict.  The execution and delivery of this Agreement by such Securityholder does not, and the performance of the terms of this Agreement by such Securityholder
          will not, (a) require the consent or approval of, or any filing with, any other Person or Governmental Entity, (b) conflict with or violate any organizational document of such Securityholder, (c) conflict with or violate or result in any breach
          of, or default (with or without notice or lapse of time, or both) under, or give to others any rights of termination, amendment, acceleration or cancellation of, or result in the creation of a Lien on, any of the Subject Securities pursuant to,
          any Contract to which such Securityholder is a party or by which such Securityholder or any of the Subject Securities are bound or (d) violate any Law applicable to such Securityholder or any of its assets (including the Subject Securities).

     

    
      
        

    

    Section 7.4          No Actions or Proceedings. There are no (a) actions, suits, claims, litigations, investigations, inquiries or proceedings commenced pending or, to the knowledge of such
          Securityholder, threatened against such Securityholder or any of its assets or (b) outstanding Orders to which any Securityholder or any of its assets are subject or bound, in each case, which could reasonably be expect to, individually or in the
          aggregate, prevent, materially delay or impair in any material respect such Securityholder’s ability to perform its obligations under this Agreement.

     

    Section 7.5          Reliance by Parent and Merger Sub. Such Securityholder understands and acknowledges that Parent and Merger Sub are entering into the Merger Agreement in reliance upon
          such Securityholder’s execution, delivery and performance of this Agreement.

     

    Section 7.6          Adequate Information.  Such Securityholder is a sophisticated investor and has adequate information concerning the business and financial condition of Parent, MOR and
          the Company to make an informed decision regarding the Merger and has independently and without reliance upon Parent, MOR or the Company and based on such information as such Securityholder has deemed appropriate, made its own analysis and
          decision to enter into this Agreement.  Such Securityholder acknowledges that neither Parent, MOR nor any of their respective Subsidiaries or Representatives has made and do not make any representation or warranty, whether express or implied, of
          any kind or character except as expressly set forth in this Agreement.  Such Securityholder acknowledges that the agreements contained herein with respect to the Subject Securities held by such Securityholder are irrevocable.

     

    Section 7.7          No Brokers.  Such Securityholder has not employed any investment banker, broker or finder in connection with the transactions contemplated by the Merger Agreement who
          is entitled to any fee or any commission from Parent or the Company or any of their respective Subsidiaries in connection with or upon consummation of the Merger or any other transaction contemplated by the Merger Agreement.

     

    ARTICLE 8

      REPRESENTATIONS AND WARRANTIES OF PARENT

     

    Parent represents and warrants to the Securityholders as of the date of this Agreement and as of the Company Stockholder Meeting as
      follows:

     

    Section 8.1          Power; Due Authorization; Binding Agreement. Parent has the requisite power and authority to execute and deliver this Agreement, to perform its obligations hereunder
          and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement and the consummation by Parent of the transactions contemplated hereby have been duly and validly authorized by all necessary corporate or other
          applicable action on the part of Parent, and no other proceedings on the part of Parent are necessary to authorize this Agreement or to consummate the transactions contemplated hereby. This Agreement has been duly and validly executed and
          delivered by Parent and, assuming the due and valid authorization, execution and delivery hereof by the other parties hereto, constitutes a valid and binding agreement of each of Parent, enforceable against Parent in accordance with its terms,
          except that (i) such enforcement may be subject to applicable bankruptcy, insolvency, reorganization, moratorium or other similar Laws, now or hereafter in effect, relating to creditors’ rights generally and (ii) equitable remedies of specific
          performance and injunctive and other forms of equitable relief may be subject to equitable defenses and to the discretion of the court before which any proceeding therefor may be brought.

     

    
      
        

    

    Section 8.2          No Conflict. The execution and delivery of this Agreement by Parent and does not, and the performance of the terms of this Agreement by Parent will not, (a) require the
          consent or approval of, or any filing with, any other Person or Governmental Entity, (b) conflict with or violate any organizational document of Parent, (c) conflict with or violate or result in any breach of, or default (with or without notice
          or lapse of time, or both) under any Contract to which Parent is a party or by which Parent is bound or (d) violate any Law applicable to Parent or any of its assets, except for any of the foregoing which would not, individually or in the
          aggregate, prevent, materially delay or impair in any material respect Parent’s ability to perform its obligations under this Agreement.

     

    ARTICLE 9

      TERMINATION

     

    Notwithstanding anything to the contrary provided herein, this Agreement and any undertaking or waiver granted by the
      Securityholders hereunder automatically shall terminate and be of no further force or effect as of the Expiration Date; provided that (i) this Article 9, Article 10 and, if the Merger is consummated, Section 6.3 and Section 6.4 shall survive any
      termination or expiration of this Agreement, (ii) any such termination shall not relieve any party from liability for any breach of its obligations hereunder prior to such termination or relieve any party from completing any obligation that arose
      hereunder in connection with the consummation of the transactions contemplated here, and (iii) each party will be entitled to any remedies at law or in equity to recover its losses arising from any such pre-termination breach.  Notwithstanding the
      foregoing, termination of this Agreement shall not prevent any party from seeking any remedies (at law or in equity) against any other party for that party’s breach of any of the terms of this Agreement prior to the date of termination.

     

    ARTICLE 10

      MISCELLANEOUS

     

    Section 10.1          No Ownership Interest.  Nothing contained in this Agreement shall be deemed to vest in Parent any direct or indirect ownership or incidence of ownership of, or with
          respect to, any Subject Security. All rights, ownership and economic benefits of and relating to the Subject Securities shall remain vested in and belong to the Securityholders, and this Agreement shall not confer any right, power or authority
          upon Parent or any other Person (a) to direct the Securityholders in the voting of any of the Subject Securities, except as otherwise specifically provided herein, or (b) in the performance of any of the Securityholders’ duties or
          responsibilities as officers or directors, as applicable, of the Company.

     

    
      
        

    

    Section 10.2          Stock Splits, etc.  In the event of any stock split, stock dividend or distribution, or any change in the Subject Securities by reason of any split-up, reverse stock
          split, recapitalization, combination, reclassification, exchange or the like, the term “Subject Securities” shall be deemed to refer to and include such Subject Securities as well as all shares distributed in such stock dividends and
          distributions and any securities into which or for which any or all of such Subject Securities may be changed or exchanged or which are received in such transaction, and such Securityholder agrees, while this Agreement is in effect, to promptly
          (and in any event within twenty-four (24) hours) notify Parent of the number of any new Subject Securities, if any, acquired by such Securityholder or any of its Affiliates after the date hereof.

     

    Section 10.3          Fees and Expenses.  All fees and expenses incurred in connection with this Agreement shall be paid by the party incurring such fees or expenses, whether or not the
          Merger consummated.

     

    Section 10.4          Notices. All notices, requests, claims, demands and other communications under this Agreement shall be in writing and shall be deemed duly given: (a) on the date of
          delivery if delivered personally; (b) on the date sent if sent by facsimile or electronic mail (provided, however, that notice given by facsimile or email shall not be effective unless either (i) a duplicate copy of such facsimile or email notice
          is promptly given by one of the other methods described in this Section 10.4 or (ii) the delivering party receives confirmation of receipt of such notice either by facsimile or email or any other method described in this Section 10.4); (c) on the
          first Business Day following the date of dispatch if delivered utilizing a next-day service by a recognized next-day courier; or (d) on the earlier of confirmed receipt or the fifth Business Day following the date of mailing if delivered by
          registered or certified mail, return receipt requested, postage prepaid.  All notices under this Agreement shall be delivered to the addresses set forth below, or pursuant to such other instructions as may be designated in writing by the party to
          receive such notice:

     

    (a)         if to the
          Securityholder to the address on Schedule 1 hereto, to:

     

    with a copy (which shall not constitute notice) to:

     

    Nelson Mullins Riley and Scarborough LLP

    4140 Parklake Ave., 2nd Floor

    Raleigh, NC 27612

    Email: david.mannheim@nelsonmullins.com

    Attn: David Mannheim

     

    (b)         if to Parent,
          to:

     

    Forian Inc.

    41 University Drive, Suite 400

    Newtown, Pennsylvania 18940

    Email: dbarton@moranalytics.com

    Attn: Dan Barton

    

    

    
      
        

    

    with a copy (which shall not constitute notice) to:

     

    Duane Morris LLP

    30 South 17th Street

    Philadelphia, PA 19103-4196

    Email: dmix@duanemorris.com

    Attn: Darrick Mix

     

    Section 10.5          Entire Agreement; No Third-Party Beneficiaries.  This Agreement, taken together with the Merger Agreement (to the extent referred to in this Agreement) and, in each
          case, any exhibit, schedule or annex thereto, constitute the entire agreement, and supersedes all prior agreements and understandings, both written and oral, between the parties with respect to the subject matter hereof.  This Agreement shall be
          binding upon and inure solely to the benefit of each party hereto, and nothing in this Agreement, express or implied, is intended to confer upon any other Person any rights or remedies of any nature whatsoever under or by reason of this Agreement
          except that the parties hereto expressly agree that the Company is intended to, and shall, be a third party beneficiary of the covenants and agreements of the parties hereto, which covenants and agreements shall not be amended, modified or waived
          without the prior written consent of the Company.

     

    Section 10.6          Amendments and Waivers. This Agreement may only be amended or waived if, and only if, such amendment or waiver is in writing and signed, in the case of an amendment, by
          each of the parties hereto, or in the case of a waiver, by the party against whom the waiver is to be effective.  The foregoing notwithstanding, no failure or delay by Parent or the Company in exercising any right hereunder shall operate as a
          waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise of any other right hereunder.

     

    Section 10.7          Severability.  If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule or Law, or public policy, (a) such term
          or other provision shall be fully separable, (b) this Agreement shall be construed and enforced as if such invalid, illegal or unenforceable provision had never comprised a part hereof, and (c) all other conditions and provisions of this
          Agreement shall nevertheless remain in full force and effect so long as either the economic or legal substance of the Merger and the other transactions contemplated by this Agreement is not affected in any manner materially adverse to any party
          or such party waives its rights under this Section 10.7 with respect thereto.  Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify
          this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner to the end that the purposes of and the transactions contemplated by this Agreement are fulfilled to the extent possible.

     

    Section 10.8          Assignment.  Neither this Agreement nor any of the rights, interests or obligations under this Agreement shall be assigned, in whole or in part, by operation of Law or
          otherwise by any of the parties without the prior written consent of the other parties; provided that the rights, interests and obligations of Merger Sub may be assigned to another direct or indirect wholly owned subsidiary of Parent.  Any
          purported assignment without such consent shall be void.  Subject to the preceding sentences, this Agreement will be binding upon, inure to the benefit of, and be enforceable by the parties and their respective successors and assigns

     

    
      
        

    

    Section 10.9          Governing Law; Jurisdiction; Waiver of Jury Trial.  THIS AGREEMENT, INCLUDING ALL MATTERS OF CONSTRUCTION, VALIDITY AND PERFORMANCE AND ANY ACTION, PROCEEDING OR
          COUNTERCLAIM (WHETHER IN CONTRACT, TORT, EQUITY OR OTHERWISE) DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT OR THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND
          ENFORCEMENT HEREOF, SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE, REGARDLESS OF THE LAWS THAT MIGHT OTHERWISE GOVERN UNDER ANY APPLICABLE PRINCIPLES OF CHOICE OR CONFLICTS OF LAWS OF THE STATE OF
          DELAWARE.

     

    Section 10.10          Jurisdiction; Venue.  Each of the parties hereto irrevocably agrees that any legal action or proceeding arising out of or relating to this Agreement brought by any
          party or its Affiliates against any other party or its Affiliates shall be brought and determined in the Court of Chancery of the State of Delaware; provided, however, that if jurisdiction is not then available in the Court of Chancery of the
          State of Delaware, then any such legal action or proceeding may be brought in any federal court located in the State of Delaware or any other Delaware state court. Each of the parties hereby irrevocably submits to the jurisdiction of the
          aforesaid courts for itself and with respect to its property, generally and unconditionally, with regard to any such action or proceeding arising out of or relating to this Agreement and the Merger and the other transactions contemplated by this
          Agreement. Each of the parties agrees not to commence any action, suit or proceeding relating thereto except in the courts described above in Delaware, other than actions in any court of competent jurisdiction to enforce any Order rendered by any
          such court in Delaware as described herein.  Each of the parties hereby irrevocably and unconditionally waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any action or proceeding arising out of or
          relating to this Agreement or the Merger or the other transactions contemplated by this Agreement, (a) any claim that it is not personally subject to the jurisdiction of the courts in Delaware as described herein for any reason, (b) that it or
          its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of
          judgment or otherwise) and (c) that (i) the suit, action or proceeding in any such court is brought in an inconvenient forum, (ii) the venue of such suit, action or proceeding is improper or (iii) this Agreement, or the subject matter hereof, may
          not be enforced in or by such courts.

     

    Section 10.11          Waiver of Jury Trial.  EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY
          SUIT, ACTION OR OTHER PROCEEDING ARISING OUT OF THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED THEREBY.  EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY
          OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH PARTY WOULD NOT, IN THE EVENT OF ANY ACTION, SUIT OR PROCEEDING, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN
          INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVER AND CERTIFICATIONS IN THIS SECTION 10.11.

     

    
      
        

    

    Section 10.12          Specific Performance.  The parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance
          with their specific terms or were otherwise breached, and that monetary damages, even if available, would not be an adequate remedy therefor.  It is explicitly agreed that the parties shall be entitled to an injunction or injunctions to prevent
          breaches or threatened breaches of this Agreement and to enforce specifically the performance of the terms and provisions of this Agreement.  It is agreed that the parties are entitled to enforce specifically the performance of terms and
          provisions of this Agreement in any court referred to in Section 10.10, without proof of actual damages (and each party hereby waives any requirement for the securing or posting of any bond in connection with such remedy), this being in addition
          to any other remedy to which they are entitled at law or in equity.  The parties further agree not to assert that a remedy of specific enforcement is unenforceable, invalid, contrary to Law or inequitable for any reason, nor to assert that a
          remedy of monetary damages would provide an adequate remedy for any such breach.

     

    Section 10.13          Interpretation.  When a reference is made in this Agreement to an Article, a Section or an Exhibit, such reference shall be to an Article, a Section or an Exhibit of or
          to this Agreement unless otherwise indicated.  The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.  Any capitalized term used in any Annex but
          not otherwise defined therein shall have the meaning assigned to such term in this Agreement.  Whenever the words “include,” “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without
          limitation.”  The words “hereof,” “hereto,” “hereby,” “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement.  The term “or”
          is not exclusive.  The word “extent” in the phrase “to the extent” shall mean the degree to which a subject or other thing extends, and such phrase shall not mean simply “if.”  The definitions contained in this Agreement are applicable to the
          singular as well as the plural forms of such terms.  All pronouns and any variations thereof refer to the masculine, feminine or neuter as the context may require.  Any agreement, instrument or Law defined or referred to herein means such
          agreement, instrument or Law as from time to time amended, modified or supplemented, unless otherwise specifically indicated.  References to a Person are also to its permitted successors and assigns.  Unless otherwise specifically indicated, all
          references to “dollars” and “$”will be deemed references to the lawful money of the U.S.  The parties hereto have participated jointly in the negotiation and drafting of this Agreement.  In the event an ambiguity or a question of intent or
          interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring by virtue of the authorship of any provisions of this Agreement.  Any
          reference to “days” means calendar days unless Business Days are expressly specified. When calculating the period of time before which, within which or following which any act is to be done pursuant to this Agreement, the date that is the
          reference date in calculating such period shall be excluded and if the last day of such period is not a Business Day, the period shall end on the next succeeding Business Day.

     

    
      
        

    

    Section 10.14          Counterparts. This Agreement may be executed in multiple counterparts, including by facsimile or by email with .pdf attachments, all of which shall be deemed an
          original and considered one and the same agreement, and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other parties.

     

     

    

    [Remainder of page intentionally left blank] 

    

    
      
        

    

    IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement, all as of the date first written above.

     

     

    

    
      	
               

            	
              Securityholder

            
	 	 
	 	Paul Hodges III
	 	 
	 	/s/ Paul Hodges III
	 	 

    

     

     

    [Signatures Continue On Next Page]

    
      
        

    

    

    

    IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement, all as of the date first written above.

     

     

    

    
      	
               

            	Securityholder
	
               

            	 	
               

            
	
               

            	 	
               

            
	
               

            	By:  

            	/s/ Terence Ferraro

              
	
               

            	Name:  

            	Terence J. Ferraro

              
	
               

            	Title:  

            	Chief Software Architect
	
               

            	 	
               

            
	
               

            	 	
               

            

    

     

    

    [Signatures Continue On Next Page]

    
      
        

    

    

    

    IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement, all as of the date first written above.

     

     

    

    
      	
               

            	Securityholder
	
               

            	
               

            	
               

            
	
               

            	Helix Opportunities LLC
	
               

            	
               

            	
               

            
	
               

            	By:  

            	/s/ Zachary Venegas

              
	
               

            	Name:  

            	Zachary Venegas

              
	
               

            	Title:  

            	Member
	
               

            	
               

            	
               

            
	 	By:  

            	/s/ Scott Ogur

              
	 	Name:  

            	Scott Ogur

              
	 	Title:  

            	Member

    

     

     

    [Signatures Continue On Next Page] 

    

    
      
        

    

    

    

    IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement, all as of the date first written above.

     

    
      	
               

            	Securityholder
	
               

            	
               

            	
               

            
	
               

            	ROSE CAPITAL FUND I, LP

              
	
               

            	By:  

              	Rose Capital Fund I GP, LLC
	
               

            	Its:  

              	General Partner
	
               

            	
               

            	
               

            
	
               

            	By:  

              	Rose Management Group LLC

              
	
               

            	Its:  

              	Manager
	 	 	 
	 	By:  

            	/s/ Jonathan Rosenthal

              
	 	Name:  

            	Jonathan Rosenthal

              
	 	Title:  

            	Member
	 	 	 
	 	By:  

            	/s/ Andrew Schweibold

              
	 	Name:  

            	Andrew Schweibold

              
	 	Title:  

            	Member
	 	 	 
	 	RSF4 II, LLC
	 	 	 
	 	By:  

            	Rose Management Group LLC, its manager
	 	 	 
	 	By:  

            	/s/ Andrew Schweibold

              
	 	Name:  

            	Andrew Schweibold

              
	 	Title:  

            	Member
	 	 	 
	 	By:  

            	/s/ Jonathan Rosenthal

              
	 	Name:  

            	Jonathan Rosenthal

              
	 	Title:  

            	Member
	 	 	 
	 	RSF4, LLC
	 	 	 
	 	By:  

            	Rose Capital Fund I GP, LLC, its Manager
	 	 	 
	 	By:  

            	/s/ Andrew Schweibold

              
	 	Name:  

            	Andrew Schweibold

              
	 	Title:  

            	Principal
	 	 	 
	 	By:  

            	/s/ Jonathan Rosenthal

              
	 	Name:  

            	Jonathan Rosenthal

              
	 	Title:  

            	Principal

    

      

    

    
      
        

    

    
      	
               

            	RSF5, LLC
	
               

            	
               

            	
               

            
	
               

            	By:  

            	/s/ Andrew Schweibold

              
	
               

            	Name:  

            	Andrew Schweibold

              
	
               

            	Title:  

            	Authorized Person
	
               

            	
               

            	
               

            
	
               

            	By:  

            	/s/ Jonathan Rosenthal

              
	
               

            	Name:  

            	Jonathan Rosenthal

              
	 	Title:  

            	Authorized Person
	 	 	 
	 	RC Feeder II, LLC
	 	 	 
	 	By:  

            	/s/ Andrew Schweibold

              
	 	Name:  

            	Andrew Schweibold

              
	 	Title:  

            	Authorized Person
	 	 	 
	 	By:  

            	/s/ Jonathan Rosenthal

              
	 	Name:  

            	Jonathan Rosenthal

              
	 	Title:  

            	Authorized Person
	 	 	 
	 	RSG5, LLC
	 	 	 
	 	By:  

            	/s/ Andrew Schweibold

              
	 	Name:  

            	Andrew Schweibold

              
	 	Title:  

            	Authorized Person
	 	 	 
	 	By:  

            	/s/ Jonathan Rosenthal

              
	 	Name:  

            	Jonathan Rosenthal

              
	 	Title:  

            	Authorized Person

    

    

     

    [Signatures Continue On Next Page]

    
      
        

    

    
      	
               

            	FORIAN INC., a Delaware corporation
	
               

            	
               

            	
               

            
	
               

            	By:	/s/ Max Wygod
	
               

            	Name:	Max Wygod
	
               

            	Title:	Executive Chairman

    

    

    
      
        

    

    SCHEDULE I

     

    	
            Name and Address

          	 	
            No. of Shares of

              Company Common Stock

          	 	
            No. of Shares of

              Company Preferred Stock

          	 	
            Company Convertible Notes (including principal amount and date of
                issuance)

          
	 	 	 	 	 	 	 
	
            Paul Hodges III

                 

          	 	
            2,500,483

             

          	 	 	 	 
	
            Terence J. Ferraro on behalf of Nightstone Unlimited, Inc.

             

          	 	
            5,207,000

             

             

          	 	 	 	 
	
            Helix Opportunities LLC

             

          	 	
            21,918,152

             

          	 	
            1,000,000

             

          	 	 
	
            Rose Capital Fund I, LP

                 

          	 	 	 	 	 	
            $1,500,000

              Issued 3/1/2019

          
	
            RSF4 II, LLC

                 

          	 	 	 	 	 	
            $385,000

              11/15/19 and 12/17/19

          
	
            RSF5 LLC

                 

          	 	
            10,150,280

             

          	 	 	 	 
	
            RSF4 LLC

                 

          	 	
            3,394,442

             

          	 	
            13,784,201

             

          	 	 
	
            RC Feeder II LLC

                 

          	 	
            1,421,889Exhibit 10.2

   

  Execution Copy

   

  CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF
    PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.

   

  License Agreement

   

  THIS LICENSE AGREEMENT (this “Agreement”) is entered into as of June 30, 2019 (“Effective Date”) by and between [***] (“Company”), a
    Delaware corporation, and Medical Outcomes Research Analytics, LLC (“Client”), a Delaware limited liability company. Company and Client are hereinafter sometimes referred to individually as a “Party” and together as the “Parties”.

   

  In consideration of the mutual promises contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
    Parties, intending to be legally bound, agree as follows:

   

  		1.	PROVISION OF SERVICES AND DATA.

   

  1.1       Services. Subject to the terms and conditions of this Agreement, Company will provide to Client the products and/or
    services identified in the attached Exhibit A (the “Deliverables” or “Services”). For purposes of this Agreement, an “Affiliate” is defined to include a Party’s subsidiaries, parent companies, and any other entities
    controlled or under common control. All references to “Company” and “Client” and all rights and obligations thereof shall include any and all of its Affiliates, as applicable.

   

  1.2       Licensed Data. Client may receive Services and/or access to data products that are: (a) compiled, created, or generated
    using Company’s proprietary databases; (b) licensed to Company directly; (c) licensed to Client where Company acts in the capacity of a database licensee; (d) syndicated reports and analyses based on sales forces or data components; (e) customized
    research and reports; and/or (f) consulting or analytical services. These data products, together with all related Deliverables in whatever media provided, whether now known or hereinafter developed, and including any Company data derived therefrom
    (but excluding Derivative Works (as defined below)) shall be collectively referred to as the “Licensed Data.” Licensed Data shall (i) at all times during the Term meet the specifications set forth in Exhibit A; (ii) at all times during
    the Term include all data field content received by Company from original sources of Licensed Data without modification other than as required by Law and to QC (including with respect to field value normalization) and deduplicate (it being understood
    that any ETL process employed by Company will not otherwise reduce such original data field content) as set forth in the data layout illustrated in Exhibit A-Attachment A to this Agreement; (iii) as of the Effective Date, include all
    prescription and medical transaction data and all EMR Data (as defined below) available to Company to license to Company’s customers; and (iv) at all times during the Term, except with respect to Additional Licensed Data (as defined below) that Client
    elects not to license hereunder, include all prescription and medical transaction data and all EMR Data then-available to Company to license to Company’s customers, and in no event less than the prescription and medical transaction data and EMR Data
    licensed by Company to other parties licensing such data. Company grants to Client and its successors and assigns a non-transferable (except as expressly set forth herein), non-exclusive, non-sublicensable (except as expressly set forth herein),
    limited right and license to use such Licensed Data solely in accordance with this Agreement. All licenses described in this Agreement are subject to Client’s compliance with the terms and conditions of this Agreement and payment of any undisputed
    amounts due.

   

  1.3       Licensed Data Use and Restrictions. The Licensed Data shall be used, stored and/or accessed in accordance with all
    applicable Laws. In addition to the rights granted to Client under Section 1.2, Company grants to Client and its successors and assigns a perpetual, non-exclusive, transferable, sublicensable, worldwide, royalty-free, right and license to use, copy,
    distribute (publicly and otherwise), display (publicly and otherwise), perform (publicly and otherwise), transmit, store, maintain and prepare derivative works of Licensed Data as needed for Client (or its successors or assigns) to develop,
    commercialize and exploit aggregations, queries, reports, enhancements or improvements to the Licensed Data (collectively, “Derivative Works”) for the benefit of customers within the permitted markets as described in Exhibit A. Client
    may disclose Company Confidential Information (including Licensed Data) to consultants, contractors, partners or suppliers (each, a “Third Party”) solely for the purpose of such Third Parties performing services for or with Client within the
    permitted markets as described in Exhibit A; provided, however, that any such Third Party has entered into an agreement with Client that contains confidentiality terms and use restrictions consistent with the terms and conditions of this
    Agreement; provided, further, however, that in the event that such Third Party will have access to Licensed Data and such Third Party will provide services other than (or in addition to) outsourced information technology assistance (including ETL,
    deduplication,

   

  

  
  
    	 	Page
            1 of 14

          	 

  

  
     

  

  
    

  cleansing, etc.) or nationally-recognized cloud/hosted storage, such Third Party has further entered into a Company-approved third party data use
    agreement substantially in the form attached hereto as Exhibit C. Except as provided in this Section 1.3, the Licensed Data shall not be: (i) copied, sold, rented, leased, transferred, or disclosed to any party without Company’s prior written
    consent, which consent shall not be unreasonably withheld, conditioned or delayed; (ii) stored, accessed, or used outside the U.S. without Company’s prior written consent (excluding with respect to Client’s use of a nationally-recognized cloud/hosted
    storage platform (e.g., Amazon Web Services, Microsoft Azure, Google Cloud)); (iii) used to identify an individual patient or an individual’s relatives or household members (other than on a de-identified anonymized basis) or to identify Company as the
    source of Licensed Data to any pharmacy or hospital provider; (iv) reengineered, reverse engineered, mashed up, linked to, used or combined with other data that would result in the re-identification of or the identification of the original source of
    Licensed Data or be in violation of applicable Law; and/or (v) published, quoted, made or reproduced for advertising, promotional or public relations purposes, reproduced or placed in any data retrieval systems (excluding with respect to Client’s use
    of a nationally-recognized cloud/hosted storage platform (e.g., Amazon Web Services, Microsoft Azure, Google Cloud)); provided however, for the avoidance of doubt, none of the above restrictions with respect to Licensed Data shall in any way apply to
    or limit in any way the use of Derivative Works. Client shall use its commercially reasonable efforts to promptly notify Company in the event it becomes aware of any use or disclosure of the Licensed Data that is not in conformity with the provisions
    of this Section 1.3. In each case of disclosure to the persons or entities expressly permitted in this Agreement, Client shall remain responsible for such persons’ and entities’ compliance with the terms and conditions of this Agreement.

   

  1.4       Compliance. The Licensed Data shall be delivered to Client in de-identified format in compliance with applicable Laws. The
    Parties, including the Party’s personnel, shall comply with all applicable laws, rules, ordinances and regulations (collectively, “Law”) relating to or affecting this Agreement or the Services. Each Party shall have the right to monitor and
    periodically audit or inspect for compliance with Law and this Agreement subject to the following terms and conditions: (i) if a Party demonstrates a good faith belief that the other Party is in breach of its obligations hereunder (the “Auditing
      Party”), then the Auditing Party shall provide written notice to the other Party describing such alleged breach; provided, however, that Client acknowledges Company shall have the right to audit Client without demonstrating a good faith belief of
    breach to the extent necessary to comply with audit rights granted by Company to the original sources of Licensed Data; (ii) if such Party is unable to address the Auditing Party’s concerns to its reasonable satisfaction within fifteen (15) days of its
    receipt of such notice, then such Party shall make available for inspection by a nationally-recognized firm of independent accountants reasonably acceptable to such Party (such consent not to be unreasonably withheld, conditioned or delayed) (the “Auditor”)
    any and all materials relevant to the alleged breach. The Party subject to the audit shall provide reasonable assistance to the Auditor and the audit shall be conducted during regular business hours upon at least fifteen (15) days prior written notice
    (which notice shall specify the purpose and scope of the audit and the time period to be audited), at the expense of the Auditing Party (which shall include the reasonable costs and expenses of the other Party in connection with any such audit unless
    any breach is determined to have occurred), and shall occur no more often than once per year during the Term. Prior to receipt of any access or information from either Party, the Auditor must execute an appropriate confidentiality agreement with
    respect to Confidential Information, which confidentiality agreement shall include restrictions on the disclosure of any Confidential Information to any third party, including the Auditing Party. The Party subject to the audit shall have the right to
    receive a copy of any such report and to discuss the basis of the conclusions reached with the Auditor and the Auditing Party. In addition, if so required by Law, each Party shall cooperate with any regulatory agency or other governmental authority
    that exercises its right to review or audit such Party’s books and records relating to the obligations under this Agreement.

   

  1.5       Contingent Rights.

   

  1.5.1       General. Company’s ability to provide the Licensed Data may be contingent upon certain corresponding rights, titles,
    interests, and licenses obtained by Company from third parties remaining in full force and effect (“Contingent Rights”) during the Term (as defined below), which Company covenants to use its commercially reasonable efforts to maintain in full
    force and effect during the Term. Should certain Company rights, titles, interests, or licenses pertaining to the Licensed Data, or any component thereof, be cancelled, terminated, rescinded, or not renewed, Client’s rights to use the previously
    delivered Licensed Data shall continue automatically and shall not constitute a breach by Client of any of its obligations under this Agreement and Company shall indemnify and hold harmless Client and its Indemnitees (as defined below) from any third
    party claims with respect thereto. Company shall provide to Client written notice as promptly as practicable (but in no event less than thirty (30) days) upon becoming aware of any actual or threatened changes to the quantity or quality of Licensed
    Data Company is able to provide and/or Company’s ability to provide the Licensed Data as described in 1.2.

   

  
  
    	 	Page
            2 of 14

          	 

  

  
     

  

  
   

  1.5.2       Licensed Data Reductions. Notwithstanding any language to the contrary set forth in this Agreement, beginning on the first
    anniversary of the Effective Date, if (i) the total volume of Licensed Data that constitutes prescription or medical transactions (excluding EMR Data (as defined below)) for any contract year during the Term declines by more than ten percent (10%) from
    the Baseline Volumes (as defined below) set forth in Exhibit A (other than with respect to EMR Data), Company and Client agree to a reduction in the Base Fees (as defined below) for the applicable contract year consistent with the actual
    percentage decrease in total Licensed Data (i.e. a twelve percent (12%) decrease in total transactions will trigger a twelve percent (12%) decrease in the Base Fees for the applicable contract year, which shall be credited to Client within ninety (90)
    days of the end of the applicable contract year); and (ii) after the first anniversary of the Effective Date, (w) the total volume of Licensed Data that constitutes prescription or medical transactions (excluding EMR Data) for any contract year during
    the Term declines by more than twenty percent (20%) from the prior contract year, (x) the total volume of Licensed Data that constitutes prescription or medical transactions (excluding EMR Data) at anytime during the Term (calculated using the trailing
    six-month transaction volume annualized) is twenty-five percent (25%) less than the applicable Baseline Volume, (y) the total volume of Licensed Data that constitutes prescription data at any time during the Term (calculated using the trailing
    six-month prescription Licensed Data volume annualized) is twenty-five percent (25%) less than the Licensed Data that constitutes the Baseline Volume of prescription data, or (z) the total volume of Licensed Data that constitutes medical data at any
    time during the Term (calculated using the trailing six-month medical Licensed Data volume annualized) is twenty-five percent (25%) less than the Licensed Data that constitutes the Baseline Volume of medical data, Company and Client agree to negotiate
    a reduction in the Base Fees consistent with the value proposition change (it being understood that in no event shall such reduction be less than the reduction in Licensed Data relative to applicable Baseline Volume). If the parties cannot agree on a
    reduction in the Base Fees following such good faith negotiations, then Client may terminate the Agreement upon thirty (30) days’ written notice to Company and shall receive a pro rata refund for Base Fees paid with respect to any period of Licensed
    Data deficiency prior thereto.

   

  1.5.3       Additional Licensed Data. Company acknowledges that Licensed Data in excess of that available as of the Effective Date (“Additional

      Licensed Data”) will be included in the license granted hereunder to the extent Company licenses additional prescription and medical transaction data or EMR Data during the Term (and Company has the right to license such data to Company’s
    customers), and agrees to provide to Client written notice as promptly as practicable of any increase in the total volume of Licensed Data relative to the Effective Date that constitutes prescription or medical transactions (excluding EMR Data) greater
    than five percent (5%) (calculated using the trailing six-month Licensed Data volume annualized). In the event that the volume of Additional Licensed Data (calculated using the trailing six-month Licensed Data volume annualized) including prescription
    or medical transactions (excluding EMR Data) constitutes more than ten percent (10%) of the total volume of like-kind (i.e., switch and/or clearinghouse-sourced medical and pharmacy transaction claims data) Licensed Data as of the Effective Date,
    Client shall have the option (with respect to the Additional Licensed Data that increases the total volume of Licensed Data ten percent (10%) or more above the Baseline Volume) as to whether to include or exclude such Additional Licensed Data within
    the Licensed Data licensed hereunder. To the extent Client elects to include such Additional Licensed Data, the Base Fees shall be increased consistent with the actual percentage increase in total Licensed Data (i.e. a twelve percent (12%) increase in
    total transactions will trigger a twelve percent (12%) increase in the Base Fees for such period that such Additional Licensed Data is included within the Licensed Data).

   

  		2.	FEES AND PAYMENT.

   

  2.1       Medical and Prescription Licensed Data Fee. Company will invoice Client pursuant to the terms set forth in Exhibit B.
    Except as set forth in Exhibit B, Client shall pay to Company (or an identified Company Affiliate) the fee amount set forth in Exhibit B for all Licensed Data that constitutes medical or prescription data (the “Base Fees” and,
    collectively with the Revenue Share Fees (as defined below), the “Fees”). Except as set forth in Exhibit B, undisputed Fees shall be paid within forty-five (45) days from the date of an invoice.

   

  2.2       EMR Data Revenue Share.

   

  2.2.1       Reporting. Within ten (10) business days after the end of each calendar quarter (“Quarter”) during the Term, Client
    shall provide to Company a system-generated report (each, a “Quarterly Report”), setting forth the revenue actually received by Client and recognized in accordance with then-applicable revenue recognition principles under GAAP for all Derivative
    Works utilizing electronic medical record or electronic medical record data (collectively, the “EMR Data”) (as provided as part of the Licensed Data) sold or licensed by Client to Client’s customers during the applicable Quarter

   

  

  
  
    	 	Page
            3 of 14

          	 

  

  
     

  

  
    

  (“Qualifying Revenue”), as the same may be adjusted for any Qualifying Revenue subsequently returned or credited to Client’s customers in
    Client’s reasonable discretion following a bona fide dispute with respect to the Derivative Works utilizing EMR Data.

   

  2.2.2       Fees and Payment Terms. In addition to the Base Fees, Client shall pay to Company [***] of the Qualifying Revenue set forth
    in each Quarterly Report (the “Revenue Share Fees”), subject to subsequent adjustment as described above. Company shall invoice Client for the Revenue Share Fees within ten (10) business days after its receipt of the Quarterly Report for such
    preceding Quarter.

   

  3.         TERM AND TERMINATION. The term of this Agreement will begin on the Effective Date and will continue through June 29, 2022 (the “Initial
      Term”), provided that Client shall have the sole right and option to extend the Term for each of three (3) successive two-year renewal periods upon delivery to Company of written notice not less than 30 days’ prior to the expiration of the then
    current Term (each such renewal period, a “Renewal Term” and collectively with the Initial Term, the “Term”). Either Party may terminate this Agreement for a material breach by the other Party upon thirty (30) days written notice
    specifying in detail the nature of the breach, unless such breach is cured within the thirty (30) day period; provided, however, for the avoidance of doubt and without limitation, Company’s failure to deliver the Deliverables timely in accordance with
    the schedule set forth in Exhibit A (other than any failure to deliver that results from Company’s loss of Contingent Rights that is remedied under Section 1.5 of this Agreement), and Client’s failure to provide payment of undisputed Fees in
    accordance with the schedule set forth in Exhibit B shall each constitute a material breach of this Agreement that requires cure within five (5) business days of written notice. A Party’s right to terminate in accordance with this Section 3
    shall be in addition to all available remedies, including a Party’s right to seek equitable relief pursuant to Section 8.6. Upon termination of this Agreement, for any reason, Client must immediately cease all uses of and destroy any and all Licensed
    Data provided to Client by Company; provided, however, that Client may retain (i) Licensed Data contained in an archived computer system back-up in accordance with security and/or disaster recovery procedures or in latent data, including deleted files
    and other non-logical data types such as memory dumps, swap files, temporary files, printer spool files and metadata that are not generally retrievable or accessible without the use of specialized tools and techniques, subject in each case to the
    destruction of such Licensed Data in due course and the inaccessibility of such Licensed Data for commercial purposes; and (ii) elements of Licensed Data incorporated into Derivative Works in accordance with the terms and conditions of this Agreement.
    For the avoidance of doubt, nothing in this Section 3 shall affect Client’s rights to Derivative Works.

   

  4.         INTELLECTUAL PROPERTY. Client acknowledges and agrees that all Licensed Data and/or Deliverables are the Intellectual Property of Company
    and/or Company’s data suppliers, may contain unpublished material and Confidential Information (as defined below), and are protected by copyright and/or other intellectual property Laws. Company acknowledges and agrees that, as between Company and
    Client, all Derivative Works, except to the extent of any Licensed Data contained therein, are the Intellectual Property of Client, may contain unpublished material and Confidential Information (as defined below), and are protected by copyright and/or
    other intellectual property Laws.

   

  5.         CONFIDENTIALITY. Each Party shall hold all confidential and proprietary information supplied to it by the other Party (the “Confidential
      Information”) in connection with this Agreement and relating to the business of such Party in confidence using the same degree of care used by the receiving Party to protect the receiving Party’s own confidential information (and in any event not
    less than a reasonable degree of care) and not disclose to third parties without the express written consent of the other Party. This confidentiality provision does not apply to any information: (i) available in the public domain through no fault of
    the receiving Party; (ii) independently developed by or on behalf of the receiving Party without reference to any Confidential Information of the disclosing Party; or (iii) disclosed to the receiving Party without restriction by a third party having a
    bona fide right to do so and not having an obligation of confidence with respect to such information. Nothing in this Agreement shall restrict a Party from disclosing any Confidential Information where the production of any such Confidential
    Information is compelled under process or request by a court or administrative or law enforcement agency of competent jurisdiction, provided that in each case the producing Party shall provide written notice to the disclosing Party (to the extent
    legally permissible) and ensure that such Confidential Information is afforded the highest level of protection via any available mechanisms for the protection of confidential or proprietary materials. Each Party shall have the right to disclose
    Licensed Data or Confidential Information to its employees, officers, directors, representatives and Third Parties but only as reasonably necessary to facilitate the Party’s performance of Services and to the extent such recipient agrees to keep the
    Licensed Data or Confidential Information confidential. All Deliverables shall be considered part of the Company Confidential Information. Derivative Works, shall not constitute Company Confidential Information.

   

  
  
    	 	Page
            4 of 14

          	 

  

  
     

  

  
   

  6.         REPRESENTATIONS; WARRANTIES; DISCLAIMER. Each Party represents and warrants to the other Party that it has the full power and authority to
    enter into and perform its obligations under this Agreement and that this Agreement is binding upon and enforceable against such Party as set forth herein. Company represents and warrants that the Services and Licensed Data delivered to Client do not:
    (a) infringe the intellectual property rights of any third party; (b) violate any Law applicable to the Services or Licensed Data; or (c) contain any viruses, Trojan horses, worms, time bombs, cancelbots or other harmful computer programming routines
    that are designed to damage, or detrimentally interfere with any system. Each Party further represents and warrants that it shall use its commercially reasonable efforts to perform its obligations hereunder, in compliance with all applicable Laws and
    consistent with industry standards. Except as expressly provided herein, any data provided to Client, including the Licensed Data, is provided “as-is.” Without limiting the generality of the foregoing, to the extent that Company delivers to Client any
    Licensed Data containing payer-level data, then Client acknowledges that any “estimated payer amount” field provided by Company in such Licensed Data is not sufficiently accurate to represent the true payer price and accordingly, should only be used by
    Client directionally and not in any contract negotiations. OTHER THAN AS EXPRESSLY SET FORTH IN THIS AGREEMENT, COMPANY MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, WITH RESPECT TO THE SERVICES AND/OR THE COMPILATION OF
      THE LICENSED DATA, INFORMATION OR OTHER DELIVERABLES INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.

   

  7.         INDEMNIFICATION; LIMITATION OF LIABILITY.

   

  7.1       Indemnification. Each Party shall indemnify, defend and hold harmless the other Party and its Affiliates, and their
    respective directors, officers, shareholders, employees, representatives, agents, attorneys, successors and assigns (the “Indemnitees”), from and against any and all alleged loss, damage or expense, claims, suits, or proceedings, including
    reasonable attorneys’ fees, asserted by any third party against any of the Indemnitees as a result of the indemnifying Party’s (or its agents and/or contractors) material breach of this Agreement, provided that the Party requesting an indemnity timely
    notifies the other Party of such claim. The indemnifying Party shall not be liable for nor be required to indemnify the other Party in regard to any injury, loss or damage to the extent that such injury, loss or damage is directly caused by any
    negligent act or omission or intentional wrongdoing by the indemnified Party or its contractors or agents.

   

  7.2       Limitations of Liability. Other than with respect to Exceptional Circumstances (as defined below) and each party’s
    indemnification obligations hereunder, in no event shall a Party be liable to the other Party for any indirect, incidental, special, exemplary, consequential or punitive damages resulting from the performance of its obligations pursuant to this
    Agreement, even if advised of the possibility of such damages, and regardless of the form in which any action is brought. Notwithstanding anything to the contrary in this Agreement, except with respect to a Party’s (i) breach of Section 5, (ii) gross
    negligence, (iii) willful misconduct or fraud (collectively, “Exceptional Circumstances”) and (iv) indemnification obligations hereunder, the maximum aggregate monetary liability of a Party in connection with the Services, the Agreement, and any
    act or omission related to the Services or Agreement, under any theory of law (including breach of contract, tort, strict liability, violation of law, and infringement) shall not exceed an amount equal to the Fees paid hereunder.

   

  8.         MISCELLANEOUS PROVISIONS.

   

  8.1       Notices. All notices, authorizations, and requests in connection with this Agreement must be in writing and will be deemed
    given: (a) on the day they are hand delivered directly to the individual designated by the receiving Party as set forth below; (b) on the day receipt is confirmed by a nationally-recognized express courier (postage prepaid; signature required) or the
    United States Post Office (postage prepaid, certified mail receipt requested); or (c) on the day of transmittal if sent by .pdf electronic format via electronic mail, provided that the recipient confirms such receipt within one (1) business day
    thereafter (and receiving Party shall use its commercially reasonable efforts to confirm such receipt). In each case, any notice must be addressed to the receiving Party as follows (or to such other address as specified upon proper notice):

   

  	
          

          If to Client:

        	 
	Electronic Notice:	mwygod@wygodco.com
	Written Notice:	Medical Outcomes Research Analytics, LLC
	 	C/O: Max Wygod
	 	443 Greenwich Street, Apt. 4C
	 	New York, New York 10013

   

  
  
    	 	Page
            5 of 14

          	 

  

  
     

  

  
   

  	If to Company:	 
	Electronic Notice:	[***]
	Written Notice:	[***]
	 	[***]
	 	[***]
	 	[***]

   

  8.2       Assignment. Neither Party may assign, sublicense, transfer or delegate this Agreement without the express prior written
    consent of the other Party, which shall not be unreasonably withheld, conditioned or delayed; provided, however, that either Party may, without the prior consent of the other Party, assign sublicense, transfer or delegate this Agreement in whole or in
    part to one or more of its Affiliates or to the successor in interest to a Party pursuant to the acquisition of a majority of the equity interests or assets of such Party. Any attempted assignment of this Agreement not in compliance with this Section 8.2
    shall be null and void. Subject to the foregoing, this Agreement will inure to and bind all successors, permitted assigns, receivers and trustees of the respective Parties hereto.

   

  8.3       Governing Law; Waiver of Trial by Jury. This Agreement shall be construed in accordance with the Laws of the State of
    Delaware, without giving effect to any conflicts of Law principles that would apply the Laws of another jurisdiction. THE PARTIES WAIVE TRIAL BY JURY IN CONNECTION WITH ANY CLAIM, ACTION, OR SUIT ASSERTED, BROUGHT, OR ARISING UNDER THIS AGREEMENT.

   

  8.4       Entire Agreement; No Waiver; Construction. This Agreement, together with any applicable exhibits, schedules, addenda, or
    other documents attached hereto or incorporated herein, contains the entire agreement between the Parties with respect to the subject matter hereof and supersedes all oral understandings, representations, prior discussions, and preliminary agreements.
    Any change, modification, or amendment of this Agreement must be in writing and signed by each Party. The failure of a Party to enforce, or the delay by a Party in enforcing, any of its rights under this Agreement will not be deemed to be a waiver or
    modification by such Party of any of its other rights. No waiver of any right, obligation, or remedy under this Agreement will be effective against either Party unless it is in writing and signed by the waiving Party. When used herein, the words
    “include” or “including” or their syntactical variants shall be deemed followed by the words “without limitation”.

   

  8.5       Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which
    together shall constitute one and the same instrument. A Party may execute this Agreement by fax or in electronic format, and a fax, .pdf, or other electronic signature of an authorized signatory of a Party will be deemed to be an original signature,
    will be valid and binding, and, upon delivery, will constitute due execution of this Agreement.

   

  8.6       Equitable Relief. Each Party acknowledges that a breach of this Agreement may irreparably harm the other Party, that the
    damages suffered by the non-breaching Party as a result of such breach will be difficult to ascertain, and that the non-breaching Party may not have an adequate remedy at law for such breach. Each Party agrees and consents that in the event of such
    breach, the non-breaching Party shall be entitled, without posting bond, in addition to all other rights and remedies to which it may be entitled to seek a decree of specific performance or an injunction requiring any such violation to be cured and
    enjoining all representatives of such Party involved from continuing the violation. The existence of any claim or cause of action that a breaching Party or any other party may have against the non-breaching Party shall not constitute a defense or bar
    the enforcement of this Section 8.6. Each Party acknowledges and agrees that the restrictions in this Section 8.6 are reasonable and necessary to protect the legitimate business interests of each Party. 

   

  IN WITNESS WHEREOF, the Parties to this Agreement have executed this Agreement by their duly authorized representatives as of the Effective Date, intending to
    be legally bound hereby.

   

  	
          

          Medical Outcomes Research Analytics, LLC

        	[***]
	 	 	 	 
	By:	/s/ Max Wygod	By:	[***]
	Name:	Max Wygod	Name:	[***]
	Title:	President	Title:	[***]
	Date:	June 30, 2019	Date:	June 30, 2019

   

  
  
    	 	Page
            6 of 14

          	 

  

  
     

  

  
   

  

  Exhibit A

   

  	Deliverable Name	Medical Outcomes Research Analytics, LLC - Weekly Prescription, Medical and EMR Data Product Deliverable
	Territory	United States
	Project Details	
          Company will develop a custom solution that will provide Client with a weekly unique and usable prescription and medical data
            product, referenced herein as Licensed Data, to be delivered on a weekly basis. The custom Licensed Data Deliverables will include the following specifications, which are subject to Company's application of its HIPAA Statistical Certification
            redaction, and in accordance with Attached A to this Exhibit A, prior to delivery in order to ensure that the Deliverables comply with all applicable Laws when delivered:

           

          Prescription Data:

          •      Inclusion of all data items within all revenue cycle related transactions

          •      Inclusion of all Patients age 2+ and within continental United States

          •      Inclusion of all Practitioners

          •      Data from all available Pharmacy Types (Retail, Mail Order, Specialty) will be included in the

          deliverable

          •      Prescription data will represent all therapeutic classes, NDCs, Forms and Strengths

          •      Claim Status (Approved, Reversed, Rejection) of the prescription as of the point in time of the

          deliverable

          •      Patients will be de-identified and tokenized with a Client-supplied Token ID that will be unique for deliveries
            to Client

           

          Medical Data:

          •     Inclusion of data items with all revenue cycle related transactions

          •     Inclusion of all Patients age 2+ and within continental United States

          •      Medical data will represent all Medical Office, Hospital, and Clinic claims and remittances

          •      Medical data will represent all ICDs. CPTs. JCodes and VCodes

          •      Medical data will represent all Practitioners

          •      Patients will be de-identified and tokenized with a Client-supplied Token ID that will be unique for deliveries
            to Client

           

          EMR Data:

          •     Inclusion of all Patients age 2+ and within continental United States

          •      EMR data will represent all Medical Office, Hospital,. and Clinic Patient encounters

          •      EMR data will represent all ICDs. CPTs. JCodes and VCodes

          •      EMR data will represent all Practitioners

          •      Patients will be de-identified and tokenized with a Client-supplied Token ID that will be unique for deliveries
            to Client

           

          The deliverables set forth in this Exhibit A, shall only be used to create Derivative Works from the
              Licensed Data for the following Permitted Uses for [***] as well as consulting and service providers supporting the same:

          [***] 

        
	 	
           

          The deliverables set forth in this Exhibit A, shall only be used to create Derivative Works from the Licensed Data for the following
            Permitted Uses for [***] as well as consulting and service providers supporting the same:

           

          [***]

        

   

  
  
    	 	Page
            7 of 14

          	 

  

  
     

  

  
   

  	 	
          Actual Table Layouts represented in Exhibit A - Attachment A

        
	Delivery and Updates	
          Anticipated Start Date: June 30, 2019

           

          First Delivery Date:

          Retrospective history on or before June 30, 2019

          Prospective data on or before June 30, 2019

           

          Final Delivery Date

          •      On or before June 30. 2022 (for Initial Term)

          •      On or before June 30, 2024 (for Renewal Term 1)

          •      On or before June 30. 2026 (for Renewal Term 2)

          •      On or before June 30, 2028 (for Renewal Term 3)

           

          Delivery Details

          •      Deliverable to include files as described in Exhibit A - Attachment A along with control report per deliverable
            file, which files shall have been subject to Company's commercially reasonable quality control processes, including normalization of field/data element definitions and field/data element values and deduplication

           

          Frequency of Delivery:

          •      Weekly

          •      Delivered within 10 calendar days after the close of the data week

           

          Delivery mode:

          •      Flat File

           

          Delivery Method:

          •      To ensure data security, Client prefers files to be transferred through Amazon S3. This requires the use of a 3rd
            party sFTP or cloud/hosted storage program that supports Amazon S3 as a host.

        
	Data Reporting Period and Baseline Volumes	
          Weekly Prescription Data Deliverable:

          First Deliverable will contain 60 months of Licensed Data from June 30, 2014-June 29, 2019, including no less than [***] pharmacy transactions consistent with the specifications set forth in this Exhibit A. Each subsequent Deliverable will be presented with the retrospective month of data in weekly deliverables.

           

          Weekly Medical and Remittance Data Deliverable:

          First deliverable will contain 60 months of data from June 30, 2014-June 29, 2019, including no less than [***] medical transactions consistent with the specifications set forth in this Exhibit A. Each subsequent deliverable will be presented with the retrospective month of data in weekly deliverables.

           

          Monthly EMR Data Deliverable:

          First deliverable will contain 60 months of data from June 30, 2014-June 29, 2019, including no less than [***] electronic medical record encounters consistent with the specifications set forth in this Exhibit A. Each subsequent deliverable will be presented with the retrospective month of data in monthly deliverables.

           

          The volumes set forth above are referred to herein individually as a "Baseline Volume" and collectively as "Baseline
              Volumes"; provided, however, that the Baseline Volume for EMR Data shall be [***] electronic medical record encounters.

        

   

  
  
    	 	Page
            8 of 14

          	 

  

  
     

    Exhibit A - Attachment A

     

    Medical Data

     

    [***]

     

  

  

  
    	 	Page 9 of 14

          	 

  

  
     

    EMR Data

     

    [***]

  

  

  

  
    	 	Page 10 of 14

          	 

  

  
     

    Prescription Data

     

    [***]

  

  

  

  
    	 	Page
            11 of 14

          	 

  

  
     

  

  
   

  EXHIBIT B

  FEES SCHEDULE

   

  LICENSED DATA FEES AND PAYMENT TERMS. Company will invoice Client the fees for Services and Deliverables as described in the Agreement, and Client will pay such
    fees within thirty (30) days for the invoice deemed “Receipt of this Signed Agreement” and forty-five (45) days following the invoicing of all other invoices. Client will use commercially reasonable efforts to submit in writing any questions or
    disputes with respect to Services or Deliverables and relating invoices promptly after its receipt of such Services, Deliverables and related invoices. In the event that an invoice for Deliverables is under dispute in good faith at the time an invoice
    for subsequent Deliverables is due, Company and Client shall negotiate in good faith to reduce the Fees due under such pending invoice proportionately until resolution of the amounts under dispute.

   

  NON-DELIVERY PENALTY. In the event that Company fails to provide Licensed Data with the specifications and on the schedule set forth in Exhibit A and
    does not cure such breach within seven (7) business days of its receipt of written notice from Client, then appropriate senior executives from Company and Client shall immediately engage in good faith negotiations in order (i) to understand the cause
    of such delay and the actions being taken by Company to remediate the delay and related timing and (ii) to determine an appropriate remedy for the failure, which may include payment to Client of a mutually agreed amount of monetary compensation until
    the earlier to occur of (i) such breach being cured and (ii) Client’s determination in its sole reasonable discretion that such monetary remedy is inadequate to address such breach and election to seek equitable relief pursuant to Section 8.6 of the
    Agreement. Client may elect to have any such amounts offset future Fees owed to Company under this Agreement or to issue an invoice for such amounts, which Company shall pay within forty-five (45) days. This non-delivery penalty is in addition to all
    available remedies, including Client’s right to terminate and to equitable relief in accordance with Sections 3 and 8.6 of the Agreement; provided, however, that this penalty shall not apply to the loss of Contingent Rights that are remediated in
    accordance with Client’s rights under Section 1.5.

   

  Unless otherwise stated, all fees must be paid in U.S. Dollars.

   

  The Base Fees and relating invoicing schedule are set forth below. The Revenue Share Fees shall be paid in accordance with Section 2.2 of the Agreement.

   

  Base Fees

   

  	Services	Annual Term	Total Cash Fee
	
          History

           

          Historical Data View May 31, 2014 - May 31, 2019

           

          [***]

        	June 30, 2014-June 29, 2019	$[***]
	
          Term Years 1, 2 and 3

           

          Weekly Prescription and Medical Licensed Data Deliverable with

          Client-Supplied Token ID:

          •      Weekly Deliverable

           

          [***]

        	
          June 30, 2019-June 29, 2020

           

        	$[***]
	
          June 30, 2020-June 29, 2021

           

        	$[***]
	
          June 30, 2021-June 29, 2022

           

        	$[***]
	 	TOTAL INITIAL TERM FEES	$[***]
	
          Renewal Term 1 (Years 4 and 5)

          Weekly Prescription and Medical Licensed Data Deliverable with

          Client-Supplied Token ID:

          •      Weekly Deliverable

           

          [***]

        	
           

          June 30, 2022 - June 29, 2023 

           

        	$[***]
	
           

          June 30, 2023 - June 29, 2024 

           

        	$[***]
	 	TOTAL
              RENEWAL TERM 1 FEES	$[***]

   

  
  
    	 	Page
            12 of 14

          	 

  

  
     

  

  
   

  	
          Renewal Term 2 (Years 6 and 7)

           

          Weekly Prescription and Medical Licensed Data Deliverable with

          Client-Supplied Token ID:

          •      Weekly Deliverable

           

          [***]

        	June 30, 2024-June
            29, 2025	$[***]
	
          

           

           

          June 30, 2025 - June 29, 2026

           

           

        	$[***]
	 	TOTAL RENEWAL TERM 2 FEES	$[***]
	
          Renewal Term 3 (Years 8 and 9)

           

          Weekly Prescription and Medical Licensed Data Deliverable with

          Client-Supplied Token ID:

          •      Weeklv Deliverable

           

          [***]

        	June 30, 2026-June 29, 2027	$[***]
	 	June 30, 2027-June 29, 2028	$[***]
	 	TOTAL RENEWAL TERM 3 FEES	$[***]
	 	 	 
	 	TOTAL TERM FEES (WITH RENEWALS)	$[***]

   

  INVOICING. All fees are quoted are exclusive of applicable taxes.

   

  	
          

          INVOICE #

        	INVOICE DATE/MILESTONE	INVOICE AMOUNT (USD)
	1	Upon Company’s Receipt of this Signed
            Agreement	$[***]
	2	1 Apr 20	$[***]
	3	1 Oct 20	$[***]
	4	1 Jan 21	$[***]
	5	1 Jun 21	$[***]
	6	1 Jan 22	$[***]
	 	
          INITIAL TERM INVOICE TOTAL AMOUNT

          (USD):

        	$[***]
	Renewal Term 1 (Years 4 and 5) 1	1 Jun 22	$[***]
	2	1 Jan 23	$[***]
	3	1 Jan 23	$[***]
	4	1Jan24	$[***]
	 	
          RENEWAL TERM 1 INVOICE TOTAL AMOUNT

          (USD)

        	$[***]
	Renewal Term 2 (Years 6 and 7) 1	1 Jun 24	$[***]
	2	1 Jan 25	$[***]
	3	1 Jun 25	$[***]
	4	1 Jan 26	$[***]
	 	
          RENEWAL TERM 2 INVOICE TOTAL AMOUNT

          (USD)

        	$[***]
	Renewal Term 3 (Years 8 and 9) 1	1 Jun 26	$[***]
	2	1 Jan 27	$[***]
	3	1 Jun 27	$[***]
	4	1 Jan 28	$[***]
	 	
          RENEWAL TERM 3 INVOICE TOTAL AMOUNT

          (USD)

        	$[***]

   

  
  
    	 	Page
            13 of 14

          	 

  

  
     

  

  
   

  EXHIBIT C

    FROM OF THIRD PARTY AGREEMENT

   

  Provided Separately

   

  
  
    	 	Page
            14 of 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}]]